Bempegaldesleukin Plus Nivolumab in First-Line Metastatic MelanomaAdi Diab, Michael E. Hurwitz, Brendan D. Curti et al.|Journal of Clinical Oncology|2021Cited by 81
420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 studyAdi Diab, Michael E. Hurwitz, Scott S. Tykodi et al.|Regular and Young Investigator Award Abstracts|2020Cited by 7